Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 6/20 | 0.48 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | DPP3 | Q9NY33 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | GRB2 | P62993 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 2/20 | 0.40 |
| ▸ | TRHR | P34981 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123433 | 0.88 | SLC6A2 (0.42) | CAPN1LNPEPANPEPCTSBDPP3 | |
| SCHEMBL29630375 | 0.88 | TRHR (0.41) | LNPEPTRHR | |
| SCHEMBL30785948 | 0.88 | SLC6A2 (0.58) | LNPEPANPEPDPP3SLC6A2OPRM1 | |
| SCHEMBL29589034 | 0.86 | TRHR (0.48) | LNPEPDPP3SLC6A2OPRM1TRHR | |
| SCHEMBL30254274 | 0.85 | OPRM1 (0.50) | SLC6A2OPRM1OPRD1RENTRHR | |
| SCHEMBL31090172 | 0.85 | SLC6A2 (0.64) | LNPEPANPEPDPP3SLC6A2OPRM1 | |
| SCHEMBL29591887 | 0.85 | REN (0.47) | CAPN1LNPEPANPEPCTSBSLC6A2 | |
| SCHEMBL31041742 | 0.84 | F2 (0.48) | LNPEPANPEPDPP3APLNROPRM1 | |
| SCHEMBL29463614 | 0.84 | CAPN1 (0.48) | CAPN1CTSBAPLNRF2REN | |
| SCHEMBL32689777 | 0.84 | CAPN1 (0.57) | CAPN1LNPEPANPEPCTSBDPP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | CAPN1 1736/4885LNPEP 1056/4885ANPEP 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.